[Mepartricin 150.000 (40 mg) vs mepartricin 50.000 U (13 mg) in the treatment of BIP. Double blind clinical trial].

Vincenzo Mirone(University of Naples Federico II), T. Lotti(University of Naples Federico II), Domenico Prezioso(Federico II University Hospital), A. Palmiéri

PubMed

April 1, 1996

Cited by 0

Related Papers

Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group

|Archivio Italiano di Urologia e Andrologia|2015|202

Prevalence, Incidence Estimation, Risk Factors and Characterization of Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Urological Hospital Outpatients in Italy: Results of a Multicenter Case-Control Observational Study

|The Journal of Urology|2007|181

Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study

|European Urology|2008|128

Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas

|International Journal of Cancer|1999|97

Italian validation of the International Consultation on Incontinence Questionnaires

|British Journal of Urology|2005|84